Organovo Holdings (ONVO) : The consensus on Organovo Holdings (ONVO) based on 2 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.
Organovo Holdings (NYSEMKT:ONVO): The stock opened at $4.05 on Wednesday but the bulls could not build on the opening and the stock topped out at $4.35 for the day. The stock traded down to $3.94 during the day, due to lack of any buying support eventually closed down at $3.97 with a loss of -1.98% for the day. The stock had closed at $4.05 on the previous day. The total traded volume was 3,048,221 shares.
The company shares have rallied 14.73% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $4.13 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $3.06 and the 200 Day Moving Average price is recorded at $2.50.
Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.